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Abstract
B cells and their progeny that produce and release anti-neutrophil cytoplasmic autoantibodies
(ANCA) are the primary cause for an aggressive form of necrotizing small vessel vasculitis.
Cytoplasmic ANCA antigens are released at the surface and in the microenvironment of cytokine-
primed neutrophils. Binding of ANCA to ANCA antigens activates neutrophils by both Fc
receptor engagement and direct Fab’2 binding to antigen on the cell surface. ANCA-activated
neutrophils release factors that induce alternative complement pathway activation, which
establishes a potent inflammatory amplification loop that causes severe necrotizing vascular
inflammation. The origin of the ANCA autoimmune response is unknown but appears to involve
genetically determined HLA specificities that allow the autoimmune response to develop. One
putative immunogenic mechanisms begins with an immune response to a peptide that is
complementary to the autoantigen and evolves through an anti-idiotypic network to produce
autoantibodies to the autoantigen. Another putative immunogenic mechanism begins with an
immune response to a microbe-derived molecular mimic of the autoantigen resulting in antibodies
that cross-react with the autoantigen. Release of neutrophil extracellular traps, apoptosis and
increased granule protein expression of ANCA antigens may facilitate the initiation of an ANCA
autoimmune response, augment established pathogenic ANCA production, or both. The ANCA B
cell autoimmune response is facilitated by quantitatively and qualitatively impaired T cell and B
cell suppression, and by release from activated neutrophils of B cell activating factors that enhance
B cell proliferation and retard B cell apoptosis.
Keywords
Antineutrophil Cytoplasmic Autoantibodies; MPO-ANCA; PR3-ANCA; Vasculitis; Microscopic
Polyangiitis; Granulomatosis with Polyangiitis
Overview of ANCA and ANCA Disease
Anti-neutrophil cytoplasmic autoantibodies (ANCA) are specific for proteins in the
cytoplasm of neutrophils and monocytes. They were first discovered in serum by indirect
immunofluorescence microscopy, which demonstrates cytoplasmic (C-ANCA) or
perinuclear (P-ANCA) staining of normal human neutrophils (Fig. 1). C-ANCA were
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discovered serendipitously by a pathologist in Australia (David Davies) who was using
normal human neutrophils as a substrate to detect anti-nuclear antibodies. He observed that a
subset of patients with focal necrotizing and crescentic glomerulonephritis had circulating
antibodies that bound to the cytoplasm of normal neutrophils [1]. Davis 1982 article [1] was
largely overlooked until a European collaborative group lead by van der Woude reported in
1985 that that C-ANCA were closely associated with Wegener’s granulomatosis (now called
granulomatosis with polyangiitis) and that ANCA titers diminished or disappeared with
response to treatment [2]. The spectrum of ANCA and ANCA disease was extended in 1988
when Falk and Jennette described P-ANCA and reported that both C-ANCA and P-ANCA
occurred not only in patients with granulomatosis with polyangiitis (Wegener’s) but also in
patients with microscopic polyangiitis and renal limited necrotizing and crescentic
glomerulonephritis that lacked well defined immunoglobulin deposits [3].
Numerous studies have confirmed that ANCA are associated with a distinctive category of
small vessel inflammation that is characterized by necrotizing inflammation of vessels and
absence or paucity of vessel wall localization of immunoglobulin and complement. This
paucity of immunoglobulin distinguishes pauci-immune ANCA-associated vasculitis and
glomerulonephritis from vasculitis and glomerulonephritis caused by extensive immune
complex accumulation in vessel walls (i.e. immune complex vasculitis), and from vasculitis
caused by in situ formation of immune complexes between vessel wall basement membrane
antigens and anti-basement membrane autoantibodies, i.e. anti-glomerular basement
membrane (anti-GBM) disease) [4]. This immunopathologic classification of small vessel
vasculitis can be accomplished using direct immunofluorescence microscopy to determine
the extent, pattern and composition of immunoglobulin deposits in vessel walls, for example
in the walls of renal glomerular capillaries (Fig. 2), dermal venules or pulmonary alveolar
capillaries.
According to the 2012 International Chapel Hill Consensus Conference Nomenclature of
Vasculitides, ANCA-associated vasculitis is defined as necrotizing vasculitis, with few or no
immune deposits, predominantly affecting small vessels, i.e., capillaries, venules, arterioles
and small arteries [4] (Fig. 3). In the acute phase, the vasculitis is characterized by
predominantly neutrophilic infiltration with extensive apoptosis and necrosis of neutrophils
resulting in extensive nuclear fragmentation (leukocytoclasia) (Fig. 3a). If this feature is
conspicuous, the descriptive term leukocytoclastic angiitis can be applied. When arteries are
affected, the acute lesions often include the spillage of plasma into necrotic vessel walls and
perivascular tissue where the coagulation cascade contacts thrombogenic stimuli and forms
fibrin, resulting in a pattern of fibrinoid necrosis (Fig. 3c). All variants of ANCA disease can
have glomerulonephritis that is characterized by segmental fibrinoid necrosis and crescent
formation (Fig. 3b), both of which result from segmental rupture of glomerular capillaries by
the inflammatory process.
ANCA vasculitis patients are further subclassified on the basis of clinical and pathologic
features into microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA)
(formerly known as Wegener’s granulomatosis) and eosinophilic granulomatosis with
polyangiitis (EGPA) (formerly known as Churg-Strauss syndrome) [4]. MPA is necrotizing
vasculitis with few or no immune deposits predominantly affecting small vessels (i.e.,
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capillaries, venules, or arterioles) in the absence of granulomatosis or a history of asthma.
Arteries may also be affected. GPA has the features of MPA with the additional feature of
necrotizing granulomatous inflammation that usually involves the upper and/or lower
respiratory tract. The vasculitic phase of EGPA is characterized by eosinophil-rich
inflammation and necrotizing granulomatous inflammation often involving the respiratory
tract, and necrotizing vasculitis predominantly affecting small to medium vessels, and
associated with asthma and eosinophilia. The early prodromal phase of EGPA has
eosinophilic inflammation in the lungs or gastrointestinal tract. ANCA only become
frequent if patients develop overt vasculitis or glomerulonephritis. The pauci-immune
necrotizing and crescentic glomerulonephritis of MPA, GPA, EGPA and renal limited
ANCA vasculitis is pathologically and immunopathologically indistinguishable.
Organ limited expressions of ANCA disease occur, for example isolated pauci-immune
necrotizing crescentic glomerulonephritis (renal-limited vasculitis) or GPA limited to the
upper respiratory tract. However, patients who initially have organ-limited disease may
subsequently develop multisystem disease.
In patients with vasculitis and glomerulonephritis, the two best characterized autoantigen
targets for ANCA are myeloperoxidase (MPO) [3] and proteinase 3 (PR3) [5–7], although
additional autoantigen targets have been detected or proposed, such as elastase [8] and
lysosome associated membrane protein 2 (LAMP2) [9]. In indirect immunofluorescence
assays, PR3-ANCA typically produce a cytoplasmic (C-ANCA) staining pattern whereas
MPO-ANCA typically produce a perinuclear (P-ANCA) staining pattern. The P-ANCA
pattern is caused by the artifactual relocation of MPO from the primary granules to the
nucleus when substrate neutrophils are fixed in alcohol prior to drying onto slides [3]. This
solubilizes the cationic MPO from the primary granules and allows it to diffuse to a stick on
the anionic nuclei (Figure 1b). PR3-ANCA and MPO-ANCA produce identical cytoplasmic
staining of formalin-fixed neutrophils in which the MPO has been covalently bound in
position by the fixative.
In North America and Europe, patients with GPA more often have PR3-ANCA than MPO-
ANCA, MPA patients have similar frequency of MPO-ANCA and PR3-ANCA, and EGPA
and renal-limited vasculitis patients have predominantly MPO-ANCA [10]. In Asia, MPO-
ANCA is more frequent than PR3-ANCA in patients with GPA as well as MPA [11]. A
genome wide association study has shown that autoantigen specificities for PR3 versus
MPO correlate better with genetic associations than the clinicopathologic phenotypes of
MPA and GPA [12]. In addition, as noted earlier, the clinical manifestations of ANCA
disease, including the patterns of organ system involvement, has different trends in patients
with MPO-ANCA compared to those with PR3-ANCA [13]. The best approach to
classifying and diagnosing ANCA disease is to specify both the serologic ANCA specificity
as well as the clinicopathologic phenotype (e.g. MPO-ANCA MPA, MPO-ANCA GPA,
PR3-ANCA MPA, PR3-ANCA GPA, MPO-ANCA EGPA, etc.) [4]. It is important to note
that approximately 10% of patients with active untreated MPA and GPA are negative for
ANCA in current conventional ANCA serologic assays, although at least some of these
patients have ANCA that can be detected by more sensitive assays [15] or assays for other
autoantigen targets [16] currently available only in research settings. Interestingly, EGPA
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patients have a high frequency of ANCA, usually MPO-ANCA, only when there is evidence
for active vasculitis and glomerulonephritis as a component of the syndrome [17].
Concurrent PR3-ANCA and MPO-ANCA is rare except in patients with some forms of
drug-induced ANCA disease [18].
Clinical Evidence that ANCA Cause Disease
As already noted, the very close association of a pathologically distinctive form of small
vessel vasculitis with ANCA at least raises the possibility of a pathogenetic link. However,
there is controversy about how well ANCA titers correlate with disease activity using the
current generation of clinical laboratory tests [19]. However, more sophisticated analytically
methods can discern the titers of pathogenic versus nonpathogenic ANCA with restricted
epitope specificities that correlate better with ANCA disease activity. For example, Roth et
al [15] used a sensitive epitope excision mass spectroscopy peptide identification technique
to identify specific epitopes on MPO that were targeted only in patients with active MPO-
ANCA disease [15]. Overall, over 20 different MPO epitopes were identified. Patients in
disease remission had MPO-ANCA directed against nonpathogenic epitopes, and even
healthy controls had very low titers of MPO-ANCA (natural autoantibodies) that reacted
with these nonpathogenic epitopes, but only patients with active disease had detectable titers
of MPO-ANCA specific for the pathogenic epitopes. Conventional ELISA using pathogenic
linear epitopes showed a strong correlation between titers of MPO-ANCA and disease
activity, whereas ELISA using nonpathogenic epitopes showed a poor correlation between
titer of MPO-ANCA and disease activity [15]. Thus, although conventional serologic assays
that use whole MPO molecules as substrate do not correlate with disease activity, epitope
specific assays do. The basis for this epitope diversity may be epitope spreading that
modulates the epitope specificity of ANCA during different phases of disease.
Another clinical observation that supports ANCA pathogenicity is the phenomenon of drug-
induced ANCA disease [18]. This illustrate the concurrent induction of the autoantibodies
and disease, and the resolution of the disease with resolution of the autoantibodies. A
mechanism for hydralazine-induced ANCA disease that has been propose [18] involves
dysregulation of ANCA antigen expression by neutrophils, which mimics a phenomenon
that has been observed in ANCA disease patients who have aberrant epigenetically
deregulated overexpression of MPO and PR3 in circulating neutrophils [20,21]. Hydralazine
is a DNA methylation inhibitor that could reverses epigenetic silencing of PR3 and MPO,
resulting in increased expression of both autoantigens in neutrophils to break tolerance and
enhance neutrophil activation by ANCA [14]. The induction of ANCA and of ANCA
disease by drugs is indirect evidence for the pathogenicity of ANCA.
Finally, the treatment response of ANCA disease supports an antibody mediated process. In
addition to anti-inflammatory therapy with corticosteroids, therapy that targets B cells (e.g.
rituximab) or reduces ANCA levels by plasma exchange is effective in ameliorating ANCA
disease [22].
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In Vitro Evidence that ANCA Can Cause Disease
If ANCA are pathogenic, they must be able to activate neutrophils and cause them to attack
small vessels. Numerous in vitro experiments document that ANCA IgG can activate primed
neutrophils causing them to release toxic oxygen radicals and destructive enzymes [23–25].
Neutrophil activation by ANCA is facilitated by priming of neutrophils, for example with
cytokines (e.g. tumor necrosis factor alpha) or bacterial products (e.g. lipopolysaccharide),
which results in the release of ANCA target antigens (e.g. MPO and PR3) at the cell surface
where they can interact with ANCA. The interaction of ANCA with ANCA antigens on the
surface of neutrophils and in the microenvironment of an inflammatory lesion activates
neutrophils predominantly by engagement of Fc receptors by ANCA complexed to antigen
[26,27] and also by ANCA Fab’2 binding to antigens on neutrophil surfaces [28,29]. ANCA
also binds to ANCA antigens that have been release into the inflammatory
microenvironment, including ANCA antigens adsorbed onto matrix and cells, such
asendothelial cells [30]. Activation of neutrophils by ANCA in vitro causes injury and death
of nearby cultured monolayers of endothelial cells [30–32], which conceptually supports a
role for ANCA-induced neutrophil activation in the pathogenesis of vasculitis. Injury to
endothelium by activated neutrophils also is likely to involve the release of neutrophil
extracellular traps (NETs) that contain many cytotoxic factors [33,34].
In Vivo Evidence that ANCA Cause Disease
The most compelling evidence that ANCA are pathogenic derives from studies in animal
models of ANCA disease. Although there are several convincing animal models of MPO-
ANCA disease that closely mimic human ANCA disease [35], there are no unequivocal
models of PR3-ANCA disease possibly because of quantitative and qualitative differences
between human and PR3in the experimental animals used to date [36]. Xiao et al, developed
the first convincing animal model of ANCA disease by injecting mouse anti-mouse anti-
MPO IgG into mice [37], which resulted in the induction of pauci-immune necrotizing and
crescentic glomerulonephritis in all mice and multiorgan necrotizing small vessel vasculitis
in some mice. The anti-mouse MPO was derived from MPO−/− mice that were immunized
with purified mouse MPO, thus the model is not a model of the genesis of an ANCA
autoimmune response, but is a model of the pathogenesis of vascular inflammation mediated
by anti-MPO IgG. Disease can be induced by injecting anti-MPO IgG into Rag2−/− mice
that lack immune-competent B-cells and T-cells, demonstrating that antibody alone is
sufficient to cause vasculitis and glomerulonephritis, and T-cells are not required [37].
Neutrophils are required for anti-MPO induced disease because depletion of neutrophils
prevents disease [38]. The importance of neutrophils in the pathogenic process was further
substantiated using a bone marrow transplantation approach to position MPO-positive
neutrophils in the bodies of MPO knockout mice [39], which demonstrated that bone
marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and
vasculitis induced by anti-MPO antibodies. As noted earlier, in vitro activation of
neutrophils by ANCA IgG is facilitated by priming of neutrophils (e.g. with tumor necrosis
factor α), which causes release of small amounts of ANCA antigens at the cell surface [23–
25]. As predicted by this in vitro observation, injecting mice with bacterial
lipopolysaccharide, which induces increased circulating tumor necrosis factor α, enhances
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the severity of glomerulonephritis induced by injection of anti-MPO [40], probably by
priming circulating neutrophils to be more activatable by anti-MPO. This is the likely
explanation for the clinical observation that onset and exacerbation of ANCA disease in
patients often corresponds to flu-like symptoms (which are evidence for elevated circulating
cytokines), for example caused by a concurrent viral respiratory tract infection.
The importance of the functional integrity of anti-MPO IgG Fc regions has been
demonstrated in the anti-MPO mouse model by showing an effect of altered Fc
glycosylation on disease induction [41]. Hydrolysis of anti-MPO IgG glycans by EndoS
attenuates anti-MPO induced neutrophil activation in vitro and prevents induction of
glomerulonephritis in mice. Systemic treatment with EndoS after disease induction
ameliorates the development of disease. The precise mechanism for this effect has not been
determined.
As noted earlier, immunohistology of glomeruli and other vessels in patients with ANCA
glomerulonephritis and vasculitis typically reveals a paucity of staining for immunoglobulin
or complement. However, most specimens have at least some deposition of immunoglobulin
and complement components, especially at the sites of inflammation. When complement
components are identified in biopsies from patients with ANCA disease, they appear to be
the result of activation of the alternative pathway of complement activation rather than the
classic or lectin pathway [42]. Additional support for the involvement of the alternative
complement pathway in human ANCA disease is the reported finding by Gou et al [43] of
elevated plasma levels of C3a, C5a, soluble C5b-9 and Bb in patients with active ANCA
disease compared to patients in remission, whereas levels of properdin were lower in active
disease than in remission and C4d levels were the same in both. These finding indicate
involvement of the alternative pathway and not the classic or lectin pathways. This
conclusion also is supported by the mouse model of ANCA disease that is induced by anti-
MPO [44–47]. In this model, ANCA disease is prevented by depleting complement with
Cobra venom factor [44] or inhibiting factor 5 [45], both of which block complement
activation by all three pathways. The absence of C4, which blocks the classic and lectin
pathways but not the alternative pathway, has no effect on disease induction, whereas the
absence of complement factor B, which blocks the alternative pathway, prevents disease
induction [44]. The apparent critical event in the participation of alternative complement
pathway activation in the pathogenesis of ANCA disease is the engagement of C5a receptors
(CD88) on neutrophils by C5a [46,47]. In fact, Anti-MPO induced disease does not occur in
mice with absence of C5a and disease can be prevented by pretreatment with a small
molecule inhibitor of the C5a receptor [47].
In vitro studies show that human and mouse neutrophils that are activated by ANCA release
an as yet unidentified factor (possibly properdin) that activates the alternative complement
pathway [44,46,48,49]. C5a is released by complement activation and binds to C5a receptors
on neutrophils, resulting in priming of neutrophils with increased release of ANCA antigens
at the cell surface. This is mediated by intracellular activation of p38 mitogen activated
protein kinase (p38MAPK), extracellular signal-regulated kinase (ERK) and phosphoinositol
3-kinase (PI3 K), and can be inhibited with bisindolylmaleimide (BIS) [48,49].
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Based on in vitro and animal model studies as well as observations in patients, Figure 4
summarizes the putative pathogenic events in ANCA vasculitis. Neutrophils that have been
primed by cytokines display ANCA antigens at the cell surface where they can be accessed
by ANCA. Binding of ANCA to ANCA antigens results in Fc receptor and Fab’2 mediated
activation of neutrophils, which in turn releases factors that activate the alternative
complement pathway. C5a generated by complement activation attracts and primes more
neutrophils resulting in amplification of the inflammatory process, and induction of the
necrotizing glomerulonephritis and vasculitis that are characteristic of ANCA disease (Fig.
3).
Origin of the ANCA Autoimmune Response
The prior sections of this review propose mechanisms by which ANCA activate neutrophils
to cause vasculitis. The remaining sections will propose how the underlying autoimmune
response arises and thrives to allow B cells to produce pathogenic ANCA. The first question
to address is the initial antigenic stimulus for an immune response that results in the
production of autoantibodies specific for MPO or PR3, or other neutrophil autoantigens that
mediated ANCA disease.
An innovative theory of the genesis of the ANCA autoimmune response posits that the
initial immune response is against complementary peptides (e.g. antisense peptides or
mimics of antisense peptides) of the autoantigen peptides, and that the autoimmune response
derives from this initial response as a consequence of anti-idiotypic responses (Fig. 4)
[50,51]. A sense peptide has an amino acid sequence that is coded for by the nucleotide
sequence of the sense strand of DNA (5′ to 3′) or by mRNA whose sequence contains the
same coding information as the sense strand of DNA. The complementary peptide has an
amino acid sequence that is coded by the complementary (antisense) strand of DNA or by
complementary mRNA with the same sequence information as the complementary strand of
DNA [52]. The definition of complementary peptides may be expanded to include peptides
whose sequence is determined by reading the nucleoside sequence of complementary
mRNA in the alternative 3′ to 5′ direction because this peptide should have a similar
hydropathic profile to a 5′ to 3′ complementary peptide because only the middle nucleoside
base of a codon or complementary codon defines the hydropathic character of an amino acid
residue [52]. Codon-directed amino acid residues in a sense peptide have specific pair-wise
interactions with the corresponding complementary codon-directed residues in
complementary peptides.
A sense protein and its complementary protein have a natural affinity for binding to each
other [52,53]. Importantly, a T cell or B cell (antibody) immune response to a
complementary protein can result in the production of T cells and immunoglobulin that
reacts with the sense protein [51,52]. In other words, immunization with an antisense
complementary peptide can induce an antibody response to the sense peptide.
PR3-ANCA patients have circulating antibodies reactive with a protein produced from PR3-
antisense RNA [50,51]. These antibodies may have been induced by an immune response
against either PR3 antisense peptides, or by peptides that mimic the antisense peptides, for
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example derived from microbes. When the amino acid sequence of a protein translated 5′–3′
from antisense RNA from the PR3 gene (PRTN3) is entered into the basic local alignment
search tool (BLAST), multiple microbial homologues of complementary PR3 are identified,
including proteins from microbes that are known to be associated with PR3-ANCA, such as
Ross River virus, Staphylococcus aureus and Entamoeba histolytica [51]. All of the patients
reported by Davis in the first published report on ANCA disease had serologic evidence for
Ross River virus infection [1] and Staph aureus infection is closely linked with disease
activity and disease phenotype in patients with GPA (Wegener’s) [54]. Theoretically,
mimics of PR3 antisense peptides derived from Ross River Virus or Staphylococcus aureus
could initiate an immune response that evolves into an autoimmune anti-PR3 response.
Patients with PR3-ANCA disease who have IgG antibodies that react with complementary
PR3 peptides would be predicted to have T cells that have antigen binding sites that react
with complementary PR3 peptides. Yang at el. reported evidence that patients with PR3-
ANCA disease have anti-complementary PR3 antibodies as well as anti-complementary
PR3-specific memory T cells directed against PR3 complementary peptide 138–169 [55]. T-
cells responsive to complementary PR3-peptide were not detected in MPO-ANCA disease
patients.
The HLA DRB1*15 allele was overrepresented in PR3-ANCA disease patients with an
immune response against sense/complementary 138–169 [55]. Interestingly, DRB1*1501
binds with high affinity to the amino acid sequences of the sense 138–169 PR3 peptide as
well as the amino acid sequence of its complementary peptide [55,56]. An important causal
role for immune recognition of this peptide epitope is suggested by the observation that
African Americans with PR3-ANCA disease have a 73.3-fold higher odds of having HLA-
DRB1*15 alleles than community-based controls [56]. In addition, sense PR3 peptides as
well as complementary PR3 peptides bind to TNF-α-induced surface expression of
DRB1*1501 on neutrophils [56]. Not all ANCA disease patients have antibodies for this
particular sense/complementary PR3 peptide, probably because different ANCA patients
have a different repertoire of epitope specificities.
Conceptually, in a patient with a predisposing antigen recognition capability, an infection by
a pathogen that has a protein that has peptides that act as mimics of PR3 or MPO antisense
peptides would initiate an appropriate antimicrobial immune response that would be
transformed into an autoimmune response by an anti-idiotypic response (Fig. 4). This
concept is supported by observations in multiple animal models of autoimmune disease in
which anti-idiotypic antibodies raised against autoantibodies induce anti-anti-idiotypes that
possess characteristics of the initial autoantibodies and caused disease after immunization
[57].
An alternative to the theory that complementary proteins or their mimics induce the ANCA
autoimmune response is that microbe-derived mimics of an autoantigen itself induce
pathogenic autoantibodies. This theory has been proposed in the context of the putative
ANCA specificity for lysosomal membrane protein-2 (LAMP2) [9], although the importance
of this specificity in patients with ANCA disease is not completely resolved [58]. Anti-
LAMP2 antibodies have been detected in patients with MPO-ANCA and PR3-ANCA as
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well as pauci-immune small vessel vasculitis that is negative for MPO-ANCA and PR3-
ANCA [9]. The human LAMP-2 epitope that is recognized has100% homology with the
bacterial adhesin FimH, and human anti-LAMP2 antibodies cross-react with bacterial FimH.
One research group reported that rats immunized with FimH develop antibodies to rat and
human LAMP-2 and develop pauci-immune necrotizing glomerulonephritis [9]. Another
research group was not able to reproduce this observation [58]. If the pathogenicity of anti-
LAMP2 antibodies is confirmed, this supports the concept that an infection with a
fimbriated bacteria could initiate an immune response against FimH that cross reacts with
human LAMP2 and mediates ANCA disease.
ANCA Antigen Presentation to B Cells
A genomewide association study has revealed HLA associations for both PR3-ANCA
disease and MPO-ANCA disease [12]. The study was performed in a discovery cohort of
1233 United Kingdom patients with ANCA-associated vasculitis and 5884 controls, and was
replicated in 1454 Northern European patients and 1666 controls. Both major-
histocompatibility-complex (MHC) and non-MHC associations were found in ANCA
disease patients. Although associations were identified with the MPA and GPA disease
phenotypes, the strongest genetic associations were with the antigenic specificity of ANCA
for PR3 versus MPO. Anti-proteinase 3 ANCA was associated with HLA-DP (P=6.2×10−89)
and the genes encoding the major inhibitor of PR3 α1-antitrypsin (SERPINA1)
(P=5.6×10−12) and proteinase 3 (PRTN3) (P=2.6×10−7). Anti-myeloperoxidase ANCA was
associated with HLA-DQ (P=2.1×10−8). These strong associations between PR3-ANCA
disease and MPO-ANCA disease and distinct HLA molecules suggest that HLA-determined
immune responses against PR3 and MPO is a central pathogenic feature of ANCA disease.
The role of HLA in antigen presentation is supported further by the observation discussed
earlier that the HLA DRB1*15 allele is overrepresented in African American PR3-ANCA
disease patients with an immune response against sense/complementary 138–169 peptide,
and that HLA DRB1*15 binds with high affinity to the amino acid sequences of the sense
138–169 PR3 peptide of its complementary peptide [55,56].
ANCA Antigen Presentation by Neutrophils
As discussed earlier, the antigenic stimulus that sets in motion a sequence of events that
leads to ANCA disease may derive from an endogenous or exogenous source. However,
there is no doubt that endogenous PR3, MPO and other potential ANCA antigen are
endogenous self antigens that are targets for ANCA. Under healthy homeostatic
circumstances, most MPO and PR3 is sequestered within the primary granules of neutrophils
and the peroxidase-positive lysosomes of monocytes. Low level stimulation (priming) of
neutrophils (and monocytes) causes low level release of MPO/PR3 at the cell surface. Full
inflammatory activation of neutrophils results in extensive extracellular release of MPO/PR3
from granules (degranulation) as well as extrusion of intracellular contents as so-called
neutrophil extracellular traps (NETs) containing chromatin strands decorated with
cytoplasmic proteins including MPO and PR3 [59]. NETs are particularly effective at
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displaying antigens to dendritic cells for internalization and subsequent presentation on HLA
molecules to facilitate immune responses, including autoimmune responses [59].
Although less explosive than full neutrophil activation with NETosis, neutrophil apoptosis
also can enhance display of ANCA antigens for an immune response, although apoptosis
may be more effective at displaying PR3 than MPO [60,61]. Neutrophil apoptosis often is
very conspicuous at sites of acute ANCA vasculitis (contributing to the leukocytoclasia) and
attracts an influx of monocytes and T cells that could result in modulation of the ANCA
autoimmune response.
Expression of the genes for the ANCA antigens MPO and PR3 is increased in the peripheral
blood neutrophils of patients with ANCA disease, which could contribute to the initiation or
modulation of the ANCA immune response [20,21,62,63]. MPO and PR3 are synthesized
and packaged into cytoplasmic granules in neutrophils and monocytes during myelogenesis
in the bone marrow. Normally, there is little or no expression of the MPO or PR3 genes in
mature peripheral blood leukocytes; however, in patients with active ANCA disease, the
expression of both proteins, as well as other neutrophil granule proteins, is increased
irrespective of whether they have MPO-ANCA or PR3-ANCA [20,21,62,63]. This abnormal
gene expression is mediated by epigenetic events that allow gene expression rather than the
usual silencing that is typical in mature circulating neutrophils [21].
NETosis, apoptosis and increased granule protein expression may facilitate the initiation of
an ANCA autoimmune response, augment established pathogenic ANCA production, or
both.
B Cell Regulation in ANCA Disease
Production of ANCA by B cells is regulated up and down by other cell types, including T
cells, B cells and neutrophils. In patients with ANCA disease, the B cell autoimmune
response appears to be facilitated by impaired T cell and B cell suppression, and by B cell
stimulation by activated neutrophils.
Multiple studies have reported that patients with ANCA disease have a deficiency in and
dysfunction of T regulatory cells (Tregs) that could contribute to the loss of tolerance that
allows the emergence and persistence of a pathogenic ANCA autoimmune response [64–
66]. Major CD4+ T helper (Th) effector cell types are distinguished according to surface
markers expressed and the effector cytokines synthesized, for example Th1 characterized by
interferon gamma production, Th2 characterized by IL-4 production, Th17 characterized by
IL-17 production, and regulatory T cells (Tregs) characterized by high expression of CD25
and FoxP3. Morgan et al observed that patients with active ANCA disease (GPA,
Wegener’s) had an increased proportion of CD4+ CD25+ T cells but the percentage of
Foxp3-positive cells was decreased [64]. They also noted that that increased circulating
CD4+ Foxp3+ cells was associated with more rapid disease remission [64]. The suppressive
function of Tregs from ANCA disease patients was markedly decreased in ANCA disease
patients with active disease but more normal during remission [65]. Free et al. reported
abnormalities in the suppressive Treg network as well as increased frequency of a distinct
proinflammatory suppression-resistant effector CD4+ T cell population in patients with
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active ANCA disease [66]. Although peripheral blood Treg cell frequency was increased in
patients with active disease the Treg cells had decreased suppressive function because of
frequent expression of a FoxP3 isoform lacking exon 2, which appeared to alter Treg
function. In addition, they identified elevated levels of a CD4+ T cell population that was
resistant to Treg suppression and produced proinflammatory cytokines. Thus, multiple
quantitative and qualitative disturbances in Tregs may contribute to insufficient suppression
of ANCA-producing B cells in patients with ANCA disease.
As with T cells, there are B cells with different functional phenotypes. High CD5 surface
expression is characteristic of some B cells with regulatory function (Bregs), which also can
be characterized by production of IL-10 [67]. In animal models of autoimmunity, Bregs
appear to ameliorate immune responses in autoimmunity [68]. In accord with this, Bunch et
al. observed that patients with active ANCA disease had lower percentages of peripheral
blood CD5+ B cells whereas patients in remission had a percentage of CD5+ B cells no
different from healthy controls [69]. Normalization of peripheral blood CD5+ B cells after
targeted B cell therapy with rituximab correlated with more effective remission [69].
Normally functioning regulatory T cells and regulatory B cells downregulate B cells that are
producing pathogenic ANCA. An opposite upregulating effect may be induced by
neutrophils that are activated by ANCA [70–74]. Activated neutrophils release many
mediators that modulate innate and adaptive immune responses, including proinflammatory,
immunoregulatory, angiogenic and fibrogenic cytokines, chemokines, and ligands of the
TNF superfamily including B-cell-activating factor (BAFF)/B lymphocyte stimulator
(BLyS) and a proliferation-inducing ligand (APRIL), which are important stimuli for B cells
that enhance proliferation and retard apoptosis [70]. Krumbholz reported that patients with
ANCA disease (GPA, Wegener’s) had elevated levels of circulating BAFF/BlyS that were
diminished by treatment [71]. Sanders et al also observed that plasma levels of BAFF were
significantly higher in patients with ANCA disease and were higher at diagnosis than at 12
months after diagnosis [72]. Nagai et al measured serum levels of APRIL and BAFF/BlyS in
patients with MPO-ANCA disease [73]. Elevated BAFF/BlyS levels, but not APRIL levels,
correlated with active disease and ANCA titer. Bader et al confirmed that BAFF/BlyS levels
are increased in patients with ANCA disease but the levels did not correlate with increased
ANCA titers [74].
Thus, in patients with ANCA disease, the B cell autoimmune response appears to be
facilitated by permissive T cell and B cell regulation, and by B cell stimulating factors
released by activated neutrophils.
Conclusion
The evidence in this review supports the primary importance of ANCA-producing B cells
and their plasma cell progeny in the pathogenesis of ANCA disease. Priming of neutrophils
with cytokines causes the release of ANCA antigen on the cell surface and in the
microenvironment. Binding of ANCA to ANCA antigens activates neutrophils by both Fc
receptor engagement and direct Fab’2 binding to antigen on the cell surface. ANCA-
activated neutrophils release factors that induce alternative complement pathway activation,
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which establishes a potent inflammatory amplification loop that causes severe necrotizing
vascular inflammation. The origin of the ANCA autoimmune response is unknown but
appears to involve genetically determined HLA specificities that allow the autoimmune
response to develop. One putative immunogenic mechanisms begins with an immune
response to a peptide that is complementary to the autoantigen and evolves through an anti-
idiotypic network to produce autoantibodies to the autoantigen. Another putative
immunogenic mechanism begins with an immune response to a microbe-derived molecular
mimic of the autoantigen resulting in antibodies that cross-react with the autoantigen.
Release of neutrophil extracellular traps, apoptosis and increased granule protein expression
of ANCA antigens may facilitate the initiation of an ANCA autoimmune response, augment
established pathogenic ANCA production, or both. The ANCA B cell autoimmune response
is facilitated by quantitatively and qualitatively impaired T cell and B cell suppression, and
by release from activated neutrophils of B cell activating factors that enhance B cell
proliferation and retard B cell apoptosis.
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Indirect immunofluorescence microscopy showing the patterns of staining of cytospin
preparations of alcohol-fixed normal human caused by ANCA. 1a: Cytoplasmic (C-ANCA)
staining pattern caused by PR3-ANCA. 1b: Perinuclear (P-ANCA) staining caused by MPO-
ANCA. (Second antibody is FITC-labeled rabbit anti-human IgG).
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Direct immunofluorescence microscopy of glomerular capillaries demonstrating granular
staining of capillary walls for IgG indicative of immune complex disease (2a), linear
staining of glomerular basement membranes (GBM) for IgG indicative of anti-GBM disease
(2b), and a paucity of staining of capillary walls for IgG in a patient with ANCA
glomerulonephritis (2c). (FITC-labeled rabbit anti-human IgG)
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Vascular inflammation is patients with ANCA disease. 1a: Leukocytoclastic angiitis
affecting a venule in the renal medulla. Note the prominent karyorrhexis of neutrophils
(leukocytoclasia). 2b: Segmental necrotizing glomerulonephritis with a focus of deeply
eosinophilic fibrinoid material with an adjacent cellular reaction (crescent). 3c. Small artery
with segmental fibrinoid necrosis in the upper right portion of the vessel wall with
intramural and perivascular infiltration of neutrophils and mononuclear leukocytes. 4d:
Pulmonary alveolar capillaritis with hemorrhage into the air spaces and numerous
neutrophils within alveolar capillaries. (Hematoxylin and eosin stain)
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Depiction of pathogenic events in ANCA vasculitis. 1) Normal unprimed neutrophils have
ANCA antigens (e.g. MPO and PR3) sequestered within cytoplasmic granules. 2)
Neutrophils that have been primed by cytokines release small amounts of ANCA antigens at
the cell surface and in the microenvironment where they are targeted by ANCA. Fc receptor
engagement by ANCA bound to ANCA antigens as well as Fab’2 binding to ANCA
antigens on the cell surface activates neutrophils. 3) Activated neutrophils release factors
that activate the alternative complement pathway with the generation of C5a. C5a is a potent
chemoattractant for neutrophils and attracts more neutrophils to the nidus of inflammation,
and C5a engages C5a receptor (CD88) resulting in additional priming of neutrophils for
activation by ANCA. 4) A potent inflammatory amplification loop is established that drives
severe necrotizing inflammation in vessel walls.
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Diagram of the putative induction of an autoimmune response by an immune response to a
peptide that is complementary to the autoantigen (e.g. autoantigen antisense peptide or
mimic of the antisense peptide). An endogenous complementary peptide (e.g. 3′to 5′
antisense peptide or 5′ to 3′ sense peptide) or an exogenous peptide (e.g. a mimic of the
antisense peptide brought in by a microbial organism) could be the target antigen #1 of an
appropriate immune response resulting in the generation of B cells #1 that produce
antibodies #1. The idiotopes of antibodies #1 are the target antigens #2.1 for antibodies #2
that are produced by B cells #2. Antibodies #2 act as both anti-idiotype antibodies for
idiotope antigens #2.1 but also as autoantibodies against the autoantigen #2.2.
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Diagram depicting the genesis, regulation and amplification of B cells that produce
pathogenic ANCA. Beginning in the upper left, genetically determined HLA antigen binding
sites present antigen that initiate T cell and B cell recognition of antigens that set in motion
the evolution of a B cell response that results in B cells and plasma cells that produce
pathogenic ANCA. This requires inefficient down regulation by T cells and B cells that
normally would suppress a pathogenic autoimmune response. Neutrophil activation by
ANCA may augment and sustain this autoimmune response by enhanced display of ANCA
autoantigens on neutrophil extracellular traps and on apoptotic neutrophils, overexpression
of ANCA antigens in neutrophils, and release of B cell activating factors. This sets up
amplification loops (curved arrows) with ANCA production activating neutrophils and
activated neutrophils in turn stimulating B cells to make more ANCA.
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